Breaking Barriers: A Scientist's Journey to Empowerment and Innovation
Get Emma’s book, The Art of Bleisure: https://www.emmalovell.au/book
Dr Dharmica Mistry is an Australian impact driven scientist and entrepreneur. She is co-founder and ex-Chief Scientist of BCAL Diagnostics and previous Head of Medtech and Biotech at Australia’s pioneer deep tech incubator, Cicada Innovations. Dharmica spent over a decade taking a research discovery through to commercialisation, developing a safe, cost-effective blood test for breast cancer detection and building national and international collaborations.
She then went on to support the medical innovation ecosystem through a number of startup and scaleup programs, providing mentorship and coaching for researchers, entrepreneurs and founding teams looking to commercialise their impactful technologies.
In her current role as Director of Diagnostics Industry Engagement at MTPConnect, she has led the development of a national action plan for the federal government on sovereign capability and resilience for diagnostic technologies.
Dharmica holds a Bachelor of Science (Honours) from University of Sydney and a PhD in Medicine from Macquarie University.
She is the recipient of a number of awards including the NSW Young Women of the Year Award in 2016; Australian Financial Review BOSS Young Executive of the Year, 2016; Macquarie University Alumni Award for Health and Medicine 2019; Australian Technologies Competition, Peoples Choice in 2017; InStyle (Magazine) Women of Style Awards, Science, 2017.
Connect with Dharmica here:
Website: https://www.linkedin.com/in/dharmicamistry/
Instagram: mistry_chronicles
More info: https://en.wikipedia.org/wiki/Dharmica_Mistry
Website https://www.emmalovell.au/
Facebook business page https://www.facebook.com/EmmaLovellAU/
Instagram https://www.instagram.com/emmalovell.au/
Linkedin: https://www.linkedin.com/in/emmalovelly/
Join me on the next Rest & Receive Retreat: https://www.emmalovell.au/srilankaretreat
Listen now on Spotifiy, itunes, and more! Link in the comments.